PharmaSGP Begins 2025 With Revenue Growth

PharmaSGP Holding SE, a German OTC pharmaceutical company, reports a 10.8% increase in revenues for the first quarter of 2025. Revenues reached €33.5 million, up from €30.2 million in the previous year. Adjusted EBITDA rose to €9.2 million compared to €8.9 million last year, with a margin of 27.5%.

CEO Peter Gerckens emphasized the company's robust organic growth and ongoing success. CFO Michael Rudolf highlighted strong core market performance, efficient financial management, and potential M&A activities, projecting continued profitable growth.

The board forecasts 2025 revenues between €122.0 million and €128.0 million, with adjusted EBITDA between €37.0 million and €39.0 million. Despite global uncertainties, PharmaSGP remains poised for another positive year.